Donval Lou, Oufkir Nina, Bondu Dorian, Daoud Eric, Dumas Elise, Reyal Fabien, Hamy Anne-Sophie
Département de chirurgie oncologique, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
Département de chirurgie oncologique, institut Curie, 35, rue Dailly, 92210 Saint-Cloud, France.
Gynecol Obstet Fertil Senol. 2022 Jul-Aug;50(7-8):535-541. doi: 10.1016/j.gofs.2022.04.005. Epub 2022 Apr 26.
To study the use of reimbursed contraceptive methods in France between 2014 and 2019, with an analysis of the profile of users by age group and an analysis by type of prescriber.
We conducted a national descriptive study using data from the Assurance Maladie Open Data database on the use of contraceptive methods reimbursed in France from January 1, 2014, to December 31, 2019. We analyzed the number of users by year, by age group (<20years, 20-60years), and by prescriber (liberal general practitioner, liberal gynecologist, hospital practitioner, liberal midwife).
In 2019, 50.1% (5,345,122) of women of childbearing age used a reimbursed contraceptive method. Hormonal oral contraception was the leading contraceptive method used (42.3%), followed by the intrauterine device (6.2%) and the implant (1.6%). Use of combined estrogen-progestogen oral contraception had been declining since 2015 (-8.1 points), to the benefit of the micro progestin pill (+9.1 points) and the copper intrauterine device (+1.4 points). Among women under 20, the hormonal implant was the second most popular contraceptive method (1.2%), followed by the copper intrauterine device (0.8%) and the hormonal intrauterine system (0.2%). Among women over 20years of age of childbearing age, the copper IUD was the second most-reimbursed contraceptive method (2.4%), followed by the hormonal intrauterine system (1.6%) and the hormonal implant (1.2%). There are disparities in prescribing practices: in 2019, 51% of prescribers were general practitioners and 97% of them prescribed hormonal oral contraception.
The contraceptive supply in France is diversifying, although oral contraception remains predominant. Disparities exist between age groups of users and there is great heterogeneity in practices among contraceptive prescribers.
研究2014年至2019年间法国报销的避孕方法的使用情况，分析不同年龄组使用者的特征，并按开处方者类型进行分析。
我们利用法国医保开放数据数据库中的数据进行了一项全国性描述性研究，该数据涉及2014年1月1日至2019年12月31日期间法国报销的避孕方法的使用情况。我们按年份、年龄组（<20岁、20 - 60岁）和开处方者（自由执业全科医生、自由执业妇科医生、医院执业医生、自由执业助产士）分析了使用者数量。
2019年，50.1%（5345122名）育龄妇女使用了报销的避孕方法。激素口服避孕药是使用最多的避孕方法（42.3%），其次是宫内节育器（6.2%）和皮下埋植剂（1.6%）。自2015年以来，复方雌激素 - 孕激素口服避孕药的使用一直在下降（下降8.1个百分点），而微型孕激素片（增加9.1个百分点）和铜宫内节育器（增加1.4个百分点）的使用则有所增加。在20岁以下的女性中，皮下埋植剂是第二受欢迎的避孕方法（1.2%），其次是铜宫内节育器（0.8%）和激素宫内节育系统（0.2%）。在20岁及以上的育龄妇女中，铜宫内节育器是第二大报销的避孕方法（2.4%），其次是激素宫内节育系统（1.6%）和皮下埋植剂（1.2%）。开处方的做法存在差异：2019年，51%的开处方者是全科医生，其中97%开了激素口服避孕药。
法国的避孕用品供应正在多样化，尽管口服避孕药仍然占主导地位。不同年龄组的使用者之间存在差异，避孕开处方者的做法存在很大异质性。
